{"gene":"RGS5","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2001,"finding":"RGS5 binds to Gαi1, Gαi2, Gαi3, Gαo, and Gαq (but not Gαs or Gα13) in the presence of GDP/AlF4-, and accelerates the GTPase activity of Gαi3, functioning as a GTPase-activating protein (GAP) for these G-protein subunits.","method":"In vitro binding assay with GDP/AlF4-, GTPase activity assay with recombinant proteins","journal":"Life sciences","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro GAP activity measurement with defined substrates","pmids":["11253162"],"is_preprint":false},{"year":2001,"finding":"RGS5 suppresses angiotensin II- and endothelin-1-induced intracellular Ca2+ transients when expressed in AT1a receptor-expressing 293T cells, confirming its role as a negative regulator of Gq-coupled GPCR signaling.","method":"Calcium transient assay in transfected 293T cells overexpressing RGS5","journal":"Life sciences","confidence":"High","confidence_rationale":"Tier 1–2 — functional assay in defined cellular system with concentration-response relationship","pmids":["11253162"],"is_preprint":false},{"year":2001,"finding":"The N-terminal region (amino acids 1–33) of RGS5 is required for membrane targeting; deletion of this region causes RGS5 to localize exclusively to the cytosolic fraction, though GAP activity is retained.","method":"Subcellular fractionation of cells expressing full-length vs. ΔN-RGS5","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — direct fractionation experiment with functional comparison","pmids":["11253162"],"is_preprint":false},{"year":1999,"finding":"The N-terminal amphipathic alpha-helix of RGS16 (amino acids 12–30), whose hydrophobic face and positively charged residues are required for membrane association, defines structural features conserved in RGS4 and RGS5, indicating a shared peripheral membrane-targeting mechanism.","method":"Site-directed mutagenesis, subcellular fractionation, differential centrifugation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 — mutagenesis with fractionation, but RGS5 involvement inferred from conservation rather than directly tested","pmids":["10391923"],"is_preprint":false},{"year":2002,"finding":"Endogenous RGS5 selectively inhibits angiotensin II AT1a receptor-mediated MAP kinase activation and inositol phosphate release through Gq/11 signaling in rat vascular smooth muscle cells, as demonstrated by ribozyme-mediated knockdown.","method":"Synthetic ribozyme knockdown, MAP kinase activation assay, inositol phosphate release assay in rat aortic smooth muscle cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with specific receptor-selective phenotypic readout, replicated across multiple assays","pmids":["12006602"],"is_preprint":false},{"year":2003,"finding":"RGS5 acts as a potent GAP for Gαi and Gαq and attenuates angiotensin II-, endothelin-1-, sphingosine-1-phosphate-, and PDGF-induced ERK-2 phosphorylation in pericyte cellular contexts.","method":"ERK-2 phosphorylation assay in cells expressing RGS5; correlation with pericyte-specific expression pattern","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — functional assays across multiple receptor-ligand pairs, consistent with in vitro GAP activity","pmids":["12514120"],"is_preprint":false},{"year":2005,"finding":"RGS4 and RGS5 are in vivo substrates of the N-end rule ubiquitin-proteasome pathway: the ATE1 arginyltransferase arginylates oxidized N-terminal Cys-2 of RGS5, targeting it for degradation via ubiquitin ligases UBR1 and UBR2; mutant RGS5 with Cys-2 blocked from becoming N-terminal is long-lived.","method":"Genetic (ATE1 knockout, UBR1/UBR2 knockout mice), mutant RGS5 stability assay in vivo and in cells","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1–2 — multiple genetic models, mutagenesis of degradation signal, replicated across RGS4/5/16","pmids":["16217033"],"is_preprint":false},{"year":2005,"finding":"Hypoxia perturbs the proteolysis of RGS5 via the N-end rule pathway, implicating an O2-ATE1-UBR1/UBR2 circuit as a mechanism coupling oxygen levels to RGS5 stability and G protein signaling.","method":"Cell-based protein stability assay under hypoxic conditions with ATE1 and UBR1/UBR2 knockouts","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — genetic and cellular models with defined molecular pathway","pmids":["16217033"],"is_preprint":false},{"year":2007,"finding":"N-terminal residues of RGS5 (specifically Cys-2 and the N-end rule determinant) control proteasomal degradation; stabilizing mutation C2S enhances RGS5 expression and function in HEK293 cells.","method":"Site-directed mutagenesis (C2S), protein expression quantification, functional assay in HEK293 cells","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis directly linking N-terminal residue to proteasomal degradation and function","pmids":["17220356"],"is_preprint":false},{"year":2007,"finding":"Protein kinase C phosphorylates RGS5 at Ser166, abolishing its binding to Gα subunits and its GAP activity; substitution of Ser166 with aspartic acid mimics phosphorylation and markedly reduces inhibition of ET-1-induced Ca2+ responses.","method":"In vitro PKC phosphorylation assay, mass spectrometry, site-directed mutagenesis (S166D), Ca2+ assay, Gα binding assay","journal":"Life sciences","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay, mass spec identification of phosphosite, mutagenesis with functional readout","pmids":["17540411"],"is_preprint":false},{"year":2008,"finding":"Loss of Rgs5 in mice results in persistently low blood pressure and dilated aortas; isolated aortic smooth muscle cells from Rgs5-/- mice show exaggerated phosphorylation of VASP and ERK in response to sodium nitroprusside or sphingosine-1-phosphate, indicating RGS5 attenuates vasodilatory signaling.","method":"Rgs5 knockout mouse, blood pressure measurement, aortic smooth muscle cell isolation, phosphorylation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with specific molecular phenotypes in isolated cells","pmids":["18268011"],"is_preprint":false},{"year":2008,"finding":"Loss of Rgs5 in tumors leads to pericyte maturation and vascular normalization, reducing tumor hypoxia and vessel leakiness, and increasing immune effector cell infiltration, establishing RGS5 as a master regulator of abnormal tumor vascular morphology through G-protein signaling.","method":"Rgs5 knockout mouse tumor model, histology, vascular permeability assay, immune cell infiltration analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO with multiple orthogonal phenotypic readouts, highly cited foundational study","pmids":["18418378"],"is_preprint":false},{"year":2009,"finding":"RGS5 is a HIF-1-dependent hypoxia-inducible gene in endothelial cells; overexpression of RGS5 induces apoptosis via caspase-3 activation and increased Bax/Bcl-2 ratio, and antagonizes VEGF angiogenic signaling by activating p38 (but not ERK1/2).","method":"HIF-1β knockout cells, RGS5 overexpression, siRNA knockdown, Annexin V assay, caspase-3 activation assay, p38 inhibitor, Matrigel assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (OE, KD, KO cell line, in vivo Matrigel) with defined pathway","pmids":["19564336"],"is_preprint":false},{"year":2011,"finding":"Beta-agonist exposure of airway smooth muscle cells reduces RGS5 expression, leading to augmented procontractile signaling; RGS5 knockdown increases agonist-evoked intracellular Ca2+ flux and myosin light chain phosphorylation, and Rgs5-/- mouse lung slices contract more to carbachol.","method":"siRNA knockdown, Ca2+ flux assay, MLC phosphorylation assay, Rgs5 KO mouse lung slice contraction assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — KD and KO with mechanistically defined cellular phenotypes","pmids":["21278382"],"is_preprint":false},{"year":2012,"finding":"RGS5 is a transcriptional target of PPARγ and PPARδ in vascular smooth muscle cells; RGS5 blunts angiotensin II-mediated protein kinase C activation and preserves large conductance Ca2+-activated K+ (BKCa) channel activity, thereby controlling myogenic tone in mesenteric arteries.","method":"Gene expression profiling, PPAR response element binding assay, siRNA targeting RGS5, patch clamp, myogenic tone measurement in transgenic mice with dominant-negative PPARγ","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods linking PPARγ→RGS5→PKC→BKCa signaling axis","pmids":["22962432"],"is_preprint":false},{"year":2013,"finding":"RGS5 acts as an endogenous repressor of hedgehog signaling: RGS5 overexpression inhibits Shh-mediated signaling and osteogenesis in C3H10T1/2 cells, while siRNA-mediated knockdown potentiates Shh signaling; RGS5 co-immunoprecipitates with Smoothened (Smo) and co-localizes with Smo in primary cilia.","method":"Overexpression, siRNA knockdown, co-immunoprecipitation, immunohistochemical analysis of primary cilia, osteogenesis assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — Co-IP, OE and KD with functional readout, localization in primary cilia","pmids":["23637832"],"is_preprint":false},{"year":2014,"finding":"RGS5 promotes arteriogenesis by inhibiting Gαq/11-mediated calcium mobilization in vascular smooth muscle cells, thereby enabling Gα12/13-mediated RhoA signaling required for SMC proliferation and acquisition of an activated phenotype; knockdown of RGS5 blocks RhoA activation and impairs collateral growth.","method":"RGS5 overexpression, siRNA knockdown, RhoA activation assay, calcium mobilization assay, Rgs5-deficient mice, collateral arteriole growth measurement","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway established through OE/KD/KO with multiple orthogonal assays","pmids":["24972930"],"is_preprint":false},{"year":2015,"finding":"GPSM3 (AGS4/G18) directly binds RGS5 selectively and enhances RGS5-mediated acceleration of GTP hydrolysis by Gαi1 in solution-based assays, while in membrane-based assays the binding of RGS5 to GPSM3 impedes GPSM3's inhibitory effect on GTP turnover.","method":"Co-immunoprecipitation, in vitro GTPase assay, membrane-based GTPase assay with M2 muscarinic receptor","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vitro biochemical assay with direct binding, single lab","pmids":["25842189"],"is_preprint":false},{"year":2017,"finding":"RGS5 localizes to and physically associates with the angiotensin II type 1 receptor (AT1R) in vascular smooth muscle cells upon AT1R activation (by AngII or mechanical stimulation), as demonstrated by proximity ligation assay; siRNA knockdown of RGS5 enhances AngII-induced constriction and myogenic responses; translocation of RGS5 to AT1R is impaired in spontaneously hypertensive rats.","method":"In situ proximity ligation assay, siRNA knockdown in intact arterioles, myogenic response measurement, candesartan competition","journal":"Hypertension","confidence":"High","confidence_rationale":"Tier 2 — direct physical interaction assay in primary VSMCs with functional loss-of-function validation","pmids":["29061726"],"is_preprint":false},{"year":2018,"finding":"Hypertensive pressure/stretch increases RGS5 expression in vascular smooth muscle cells; RGS5 is required for hypertension-induced RhoA activation and stress fiber formation through its inhibition of Gαq/11 signaling, thereby enabling the synthetic VSMC phenotype; PKC inhibition mimics RGS5-mediated effects on RhoA.","method":"Rgs5 KO mice, mechanical stretch experiments, RhoA activation assay, PKC inhibition, SMC phenotype markers","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — KO model with mechanistic dissection of Gαq/11→PKC→RhoA pathway","pmids":["29208700"],"is_preprint":false},{"year":2021,"finding":"In the tumor microenvironment, TGFβ causes pSmad2 to bind RGS5 and traffics it to the nucleus, suppressing both RGS5-Gαi/q signaling and pSmad2/3-Smad4 pairing; this switches RGS5 from pro-apoptotic to anti-apoptotic by rescuing PI3K-AKT signaling and preventing mitochondrial damage/caspase activation in tumor pericytes.","method":"Co-immunoprecipitation, nuclear fractionation, PI3K-AKT signaling assay, apoptosis assays (Bcl2, PUMA, Bax, caspase), pericyte survival assays","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — multiple binding and functional assays defining a novel RGS5-TGFβ-Smad2 signaling axis","pmids":["34012071"],"is_preprint":false},{"year":2021,"finding":"ATE1-mediated arginylation controls RGS5 turnover, which in turn regulates β-catenin stability via GSK3-β; RGS5 loss-of-function or gain-of-function modulates Wnt/β-catenin signaling in liver cancer cells, with CHIR99021 (GSK3-β inhibitor) cooperative effects confirming the pathway order.","method":"Loss- and gain-of-function (lentivirus, siRNA), co-immunoprecipitation with β-catenin, GSK3-β inhibitor epistasis","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis and OE/KD with pathway placement, single lab","pmids":["34158395"],"is_preprint":false},{"year":2021,"finding":"RGS5 overexpression in proliferating VSMCs attenuates ERK1/2 and Akt phosphorylation and promotes a resting/quiescent phenotype; selective inhibition of Gαi/o (but not Gαq/11) mimics this effect, indicating RGS5 maintains VSMC growth arrest primarily through Gαi/o suppression.","method":"RGS5 overexpression, microarray-based expression profiling, Gαi/o and Gαq/11 selective inhibitors, ERK1/2 and Akt phosphorylation assays, proliferation and migration assays","journal":"Cells","confidence":"High","confidence_rationale":"Tier 2 — pharmacological dissection of G-protein subtype with OE and multiple functional readouts","pmids":["34359918"],"is_preprint":false},{"year":2022,"finding":"RGS5 acts as a hypoxia-responsive protein in human brain pericytes that is stabilized under hypoxia independently of HIF-1α; RGS5 expression desensitizes pericytes to PDGFBB and sphingosine-1-phosphate signaling, blocking chemokinesis and chemotaxis induced by these factors.","method":"Hypoxia experiments with HIF-1α inhibition, PDGFBB/S1P chemokinesis and chemotaxis assays, RGS5 overexpression in brain pericytes","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays in primary cells with HIF-1α independence shown, single lab","pmids":["36111549"],"is_preprint":false},{"year":2019,"finding":"RGS5 inhibits calcium-sensing receptor (CASR) signaling in parathyroid cells; overexpression of RGS5 in parathyroid gland causes hyperparathyroidism, parathyroid neoplasia, and elevated PTH in transgenic mice, while RGS5-null mice have abnormally low PTH levels.","method":"Transgenic mouse overexpressing RGS5 in parathyroid, Rgs5-null mouse, CASR signaling assay in normal human parathyroid cells","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — both overexpression and KO mouse models with defined CASR signaling mechanism","pmids":["30690792"],"is_preprint":false},{"year":2017,"finding":"RGS5 inhibits Sonic Hedgehog (Shh) signaling in cortical neurons: RGS5 overexpression reduces neurite outgrowth and FM4-64 uptake (presynaptic terminal function) and affects cAMP-PKA signaling, consistent with its GAP activity on Gαi downstream of Smo.","method":"Adenoviral RGS5 overexpression in primary cortical neurons, neurite outgrowth quantification, FM4-64 uptake assay, cAMP-PKA assay","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 — functional neuronal assays with OE, single lab","pmids":["28684360"],"is_preprint":false},{"year":2023,"finding":"RGS5 promotes neuroinflammation by binding directly to TNFR1 and TNFR2 in astrocytes, augmenting TNF signaling-mediated pro-inflammatory cytokine production; selective ablation of Rgs5 in astrocytes mitigates neuroinflammatory response in Parkinson's disease models.","method":"Astrocyte-specific Rgs5 conditional knockout, Rgs5 overexpression, Co-immunoprecipitation of RGS5 with TNFR1/TNFR2, cytokine production assays, PD animal models","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 — cell-specific KO + OE + direct physical interaction (Co-IP) with defined functional readouts","pmids":["37674228"],"is_preprint":false},{"year":2024,"finding":"Age-dependent loss of RGS5 in cardiac pericytes impairs cardiac function and induces myocardial fibrosis; RGS5-deficient pericytes adopt a profibrotic gene expression signature, secreting TGFB2 and PDGFB, and the conditioned medium activates fibroblasts (αSMA induction) in a TGFβ2-dependent manner.","method":"In vivo RGS5 deletion, pericyte-fibroblast co-culture, supernatant transfer experiment, TGFβ2 neutralization, single-nucleus RNA sequencing, histological analysis","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO + in vitro co-culture + mechanistic rescue experiments","pmids":["38563133"],"is_preprint":false},{"year":2006,"finding":"The complex of human Gαi3 and RGS5 with GDP/Mg2+/AlF4- was crystallized at 3.0 Å resolution (space group P4(1)2(1)2, unit cell a=b=95.9 Å, c=138.8 Å), providing preliminary structural characterization of the RGS5-Gαi3 interaction.","method":"Protein overexpression in E. coli, complex crystallization, X-ray crystallography (synchrotron source)","journal":"Protein and peptide letters","confidence":"Low","confidence_rationale":"Tier 1 method but only preliminary crystallographic report without functional validation","pmids":["17100651"],"is_preprint":false},{"year":2005,"finding":"A novel splice variant of RGS5 (RGS5s), lacking 108 N-terminal amino acids, localizes exclusively to the cytosolic fraction unlike full-length RGS5, and fails to inhibit Gαq-coupled AT1 or FP receptor Ca2+ signaling; co-transfection of RGS5s with RGS5 competitively blocks full-length RGS5 function.","method":"RT-PCR cloning, subcellular fractionation, Ca2+ signaling assay, co-transfection competition assay in HEK293 cells","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — direct fractionation and functional assay with dominant-negative characterization","pmids":["15670159"],"is_preprint":false},{"year":2007,"finding":"RGS5 forms a homodimer in addition to its monomeric form; the dimer is longer-lived than the monomer, suggesting it may serve a regulatory function in GPCR signaling.","method":"Western blot, GFP-tagged RGS5 yeast assay, two-hybrid assay, HEK293A cell analysis","journal":"Cellular physiology and biochemistry","confidence":"Low","confidence_rationale":"Tier 3 — dimerization shown by multiple methods but functional significance only inferred from stability","pmids":["17762159"],"is_preprint":false},{"year":2012,"finding":"Loss of Rgs5 in mice results in prolonged cardiac repolarization (extended QT interval and action potential duration), reduced outward voltage-dependent K+ currents (Ito, IKur, Iss), and downregulated Kv4.2, Kv4.3, Kv1.5, and Kv2.1, predisposing to ventricular tachyarrhythmia.","method":"Rgs5 KO mouse, in vivo/in vitro electrophysiology, whole-cell patch clamp, Western blot and transcript analysis of Kv channels","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 — KO mouse with direct electrophysiological measurements at organ, cell, and molecular levels","pmids":["23079193"],"is_preprint":false},{"year":2023,"finding":"RGS5 co-immunoprecipitates with c-Myc in gastric cancer cells and regulates c-Myc protein levels through the ubiquitin-proteasome pathway, thereby controlling mismatch repair protein expression and PD-L1 levels.","method":"Co-immunoprecipitation of RGS5 and c-Myc, ubiquitin-proteasome pathway inhibition, Western blot","journal":"Molecular carcinogenesis","confidence":"Low","confidence_rationale":"Tier 3 — single Co-IP with limited mechanistic follow-up","pmids":["38860604"],"is_preprint":false}],"current_model":"RGS5 is a peripheral membrane-associated GTPase-activating protein (GAP) for Gαi and Gαq subunits, whose N-terminal region (including a conserved amphipathic helix) directs membrane targeting; its stability is regulated by the N-end rule pathway through sequential N-terminal Cys-2 oxidation, arginylation by ATE1, and proteasomal degradation via UBR1/UBR2, while PKC phosphorylation at Ser166 inactivates its GAP function; in vascular smooth muscle cells and pericytes, RGS5 selectively attenuates angiotensin II/AT1R, endothelin-1, sphingosine-1-phosphate, and PDGF-mediated signaling to regulate arterial tone, vascular remodeling (via Gαq/11→PKC suppression enabling Gα12/13→RhoA activation), and blood pressure, and also suppresses hedgehog signaling via Gαi inhibition downstream of Smoothened, binds TNFR1/TNFR2 in astrocytes to amplify TNF-driven neuroinflammation, and in the tumor microenvironment is co-opted by TGFβ through pSmad2-RGS5 nuclear complex formation to switch from pro-apoptotic to pro-survival signaling in pericytes."},"narrative":{"teleology":[{"year":1999,"claim":"Establishing the structural basis for membrane targeting: mutagenesis of RGS16 defined an N-terminal amphipathic helix whose hydrophobic face and charged residues are required for peripheral membrane association, a feature conserved in RGS5.","evidence":"Site-directed mutagenesis and subcellular fractionation of RGS16, with conservation analysis to RGS4/RGS5","pmids":["10391923"],"confidence":"Medium","gaps":["The amphipathic helix was characterized in RGS16, not RGS5 directly","Lipid-binding specificity of the helix is unknown"]},{"year":2001,"claim":"Defining RGS5 as a selective GAP for Gαi and Gαq established its core biochemical activity and showed it suppresses Gq-coupled GPCR (AT1R, ET-1) calcium signaling, answering which G-protein subtypes it acts on.","evidence":"In vitro GAP assay with recombinant proteins; calcium transient assays in AT1a-expressing 293T cells; subcellular fractionation showing N-terminal 33 residues required for membrane targeting","pmids":["11253162"],"confidence":"High","gaps":["No structural detail of Gα–RGS5 interface at this point","Endogenous relevance in native cells not yet shown"]},{"year":2002,"claim":"Loss-of-function in native vascular smooth muscle cells demonstrated that endogenous RGS5 selectively restrains AT1R-Gq/11 signaling (MAPK, inositol phosphate) but not other GPCRs, establishing receptor selectivity in a physiological context.","evidence":"Ribozyme-mediated RGS5 knockdown in rat aortic smooth muscle cells with MAPK and IP release readouts","pmids":["12006602"],"confidence":"High","gaps":["Mechanism of receptor selectivity (direct AT1R interaction vs. subcellular compartmentalization) unresolved"]},{"year":2003,"claim":"Broadening the ligand repertoire showed RGS5 attenuates signaling from multiple GPCR agonists (AngII, ET-1, S1P, PDGF) relevant to pericyte biology, positioning it as a multi-receptor signaling brake in the vasculature.","evidence":"ERK-2 phosphorylation assays across multiple ligands in pericyte-relevant cellular contexts","pmids":["12514120"],"confidence":"High","gaps":["Pericyte-specific phenotypic consequences not yet tested in vivo"]},{"year":2005,"claim":"The discovery that RGS5 is degraded via the N-end rule pathway — requiring Cys-2 oxidation, ATE1-mediated arginylation, and UBR1/UBR2 ubiquitin ligases — and that hypoxia perturbs this degradation, revealed an oxygen-sensing mechanism controlling RGS5 protein levels.","evidence":"ATE1-KO and UBR1/UBR2-KO mice, Cys-2 mutant stability assays, hypoxia experiments","pmids":["16217033"],"confidence":"High","gaps":["Identity of the oxidase acting on Cys-2 remains unknown","In vivo vascular consequences of hypoxia-stabilized RGS5 not directly tested"]},{"year":2005,"claim":"A short splice variant (RGS5s) lacking 108 N-terminal residues is cytosolic and GAP-inactive, and acts as a dominant-negative competitor, revealing a potential endogenous regulatory mechanism.","evidence":"RT-PCR cloning, fractionation, calcium assays, and co-transfection competition in HEK293 cells","pmids":["15670159"],"confidence":"Medium","gaps":["Physiological expression levels and tissue distribution of RGS5s unclear","In vivo relevance of dominant-negative function not established"]},{"year":2007,"claim":"Identification of PKC-mediated phosphorylation at Ser166 as a switch that abolishes Gα binding and GAP activity provided a feedback mechanism by which Gαq→PKC signaling can inactivate its own negative regulator.","evidence":"In vitro PKC assay, mass spectrometry of Ser166, S166D phosphomimetic mutagenesis with Ca2+ and Gα-binding readouts","pmids":["17540411"],"confidence":"High","gaps":["Which PKC isoform(s) are responsible in vivo is not defined","Whether Ser166 phosphorylation is reversible by specific phosphatases is unknown"]},{"year":2008,"claim":"Rgs5-knockout mice revealed two major in vivo roles: systemic hypotension with exaggerated vasodilatory signaling in aortic SMCs, and pericyte-driven tumor vascular normalization upon RGS5 loss, establishing RGS5 as a regulator of both arterial tone and tumor vasculature.","evidence":"Rgs5-KO mice with blood pressure measurement, aortic SMC phosphorylation assays; tumor transplant models with vascular permeability, immune infiltration, and histology","pmids":["18268011","18418378"],"confidence":"High","gaps":["Downstream effectors mediating tumor vascular normalization not fully delineated","Whether RGS5 loss affects immune evasion independently of vascular normalization is unclear"]},{"year":2009,"claim":"RGS5 was identified as a HIF-1-dependent hypoxia-responsive gene that induces caspase-3-mediated apoptosis and antagonizes VEGF signaling via p38 activation, linking its expression to oxygen-sensing transcriptional programs.","evidence":"HIF-1β-KO endothelial cells, RGS5 overexpression and siRNA knockdown, Annexin V and caspase-3 assays, p38 inhibitor studies","pmids":["19564336"],"confidence":"High","gaps":["Whether HIF-1-dependent transcription and N-end rule protein stabilization operate synergistically or redundantly under hypoxia"]},{"year":2012,"claim":"Two new physiological roles were defined: RGS5 controls cardiac repolarization via regulation of voltage-dependent K+ channels (Kv4.2/4.3, Kv1.5, Kv2.1), and in VSMCs it is a PPARγ/δ transcriptional target that preserves BKCa channel activity to control myogenic tone by suppressing PKC.","evidence":"Rgs5-KO mouse electrophysiology (QT prolongation, patch clamp, Kv channel expression); PPARγ response element binding, siRNA, patch clamp, myogenic tone in transgenic mice","pmids":["23079193","22962432"],"confidence":"High","gaps":["Mechanism linking RGS5 loss to Kv channel downregulation is indirect — whether transcriptional or post-translational is unknown","Whether PPARγ regulation of RGS5 is relevant outside the mesenteric vasculature"]},{"year":2013,"claim":"RGS5 was shown to repress hedgehog signaling by co-immunoprecipitating with Smoothened and co-localizing in primary cilia, with overexpression inhibiting and knockdown potentiating Shh-mediated osteogenesis, extending its function beyond classical Gαi/q signaling.","evidence":"Co-IP, immunohistochemistry in primary cilia, OE and siRNA in C3H10T1/2 cells with osteogenesis readout","pmids":["23637832"],"confidence":"High","gaps":["Whether RGS5 acts on Gαi downstream of Smo or through a direct Smo interaction is unresolved","In vivo hedgehog-related phenotype in Rgs5-KO mice not reported"]},{"year":2014,"claim":"A signaling switch model was established: RGS5 preferentially inhibits Gαq/11→PKC, thereby enabling Gα12/13→RhoA signaling in VSMCs — explaining how RGS5 promotes arteriogenesis by balancing competing G-protein pathways rather than uniformly suppressing all signaling.","evidence":"OE/KD/KO approaches with RhoA activation, calcium mobilization, and collateral arteriole growth measurements","pmids":["24972930"],"confidence":"High","gaps":["How RGS5 achieves selectivity for Gαq/11 over Gα12/13 at the structural level is unknown"]},{"year":2017,"claim":"Proximity ligation demonstrated that RGS5 physically associates with AT1R upon activation in VSMCs, and this translocation is impaired in spontaneously hypertensive rats, providing a mechanism for receptor-proximal GAP activity and its failure in hypertension.","evidence":"In situ PLA in primary VSMCs, siRNA knockdown with myogenic response measurement, comparison of normotensive vs. SHR arterioles","pmids":["29061726"],"confidence":"High","gaps":["Whether impaired RGS5 translocation in SHR is cause or consequence of hypertension","Direct binding interface between RGS5 and AT1R not mapped"]},{"year":2018,"claim":"Mechanical stretch/hypertensive pressure was shown to upregulate RGS5 in VSMCs, which then enables RhoA-mediated stress fiber formation through Gαq/11 suppression, establishing RGS5 as a mechanosensitive effector of vascular remodeling.","evidence":"Rgs5-KO mice under hypertension, mechanical stretch of VSMCs, RhoA assay, PKC inhibitor phenocopy","pmids":["29208700"],"confidence":"High","gaps":["Transcriptional mechanism by which stretch induces RGS5 expression is not defined"]},{"year":2019,"claim":"RGS5 inhibits calcium-sensing receptor signaling in parathyroid cells: transgenic overexpression causes hyperparathyroidism and parathyroid neoplasia while Rgs5-null mice have low PTH, revealing an endocrine role beyond the vasculature.","evidence":"Parathyroid-targeted RGS5 transgenic and Rgs5-null mice, CASR signaling in human parathyroid cells","pmids":["30690792"],"confidence":"High","gaps":["Whether RGS5 acts on Gαi or Gαq downstream of CASR is not dissected","Relevance to human parathyroid disease not established"]},{"year":2021,"claim":"TGFβ-induced pSmad2 was found to bind RGS5 and sequester it to the nucleus in tumor pericytes, switching RGS5 from a pro-apoptotic to pro-survival factor by rescuing PI3K-AKT signaling, revealing how the tumor microenvironment co-opts RGS5.","evidence":"Co-IP of pSmad2–RGS5, nuclear fractionation, PI3K-AKT and apoptosis assays in tumor pericytes","pmids":["34012071"],"confidence":"High","gaps":["Whether nuclear RGS5 has transcriptional or other nuclear functions beyond Smad2 sequestration","Generalizability across tumor types not tested"]},{"year":2021,"claim":"RGS5 overexpression in proliferating VSMCs was shown to promote quiescence primarily through Gαi/o suppression (attenuating ERK1/2 and Akt), pharmacologically dissecting which Gα subtype mediates the growth-arrest phenotype.","evidence":"OE with selective Gαi/o vs. Gαq/11 inhibitors, ERK/Akt phosphorylation, proliferation and migration assays","pmids":["34359918"],"confidence":"High","gaps":["Identity of the Gαi-coupled receptor driving VSMC proliferation that RGS5 opposes is not specified"]},{"year":2023,"claim":"A non-canonical, G-protein-independent function was identified: RGS5 directly binds TNFR1 and TNFR2 in astrocytes to amplify TNF-driven neuroinflammation, and astrocyte-specific Rgs5 deletion mitigates neuroinflammation in Parkinson's disease models.","evidence":"Astrocyte-specific conditional Rgs5-KO, Co-IP of RGS5 with TNFR1/TNFR2, cytokine assays, PD animal models","pmids":["37674228"],"confidence":"High","gaps":["Mechanism by which RGS5 binding to TNFRs amplifies signaling (scaffolding, receptor stabilization?) is undefined","Whether this is Gα-dependent or entirely independent is unresolved"]},{"year":2024,"claim":"Age-dependent loss of RGS5 in cardiac pericytes was shown to drive myocardial fibrosis through secretion of TGFβ2 and PDGFB, which activate fibroblasts in a paracrine manner, establishing RGS5 as a guardian against cardiac aging.","evidence":"In vivo Rgs5 deletion, pericyte-fibroblast co-culture, TGFβ2 neutralization rescue, snRNA-seq, histology","pmids":["38563133"],"confidence":"High","gaps":["What triggers age-dependent RGS5 downregulation in pericytes is unknown","Whether restoring RGS5 can reverse established fibrosis is untested"]},{"year":null,"claim":"Key open questions include the structural basis of RGS5 selectivity for Gαq/11 over Gα12/13, the identity of the Cys-2 oxidase, whether nuclear RGS5–pSmad2 complexes have transcriptional roles, and the mechanism by which RGS5 binding to TNFRs amplifies rather than dampens signaling.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of full-length RGS5 or its TNFR complexes","Cys-2 oxidase identity unknown","Nuclear function of RGS5 beyond Smad sequestration uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[0,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,4,5,9,16,22]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,29]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20]},{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,4,5,9,15,16,18,22,24,25]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[6,7,8]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[12,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[26]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[15,25]}],"complexes":[],"partners":["GNAI3","GNAQ","ATE1","UBR1","UBR2","SMO","TNFRSF1A","SMAD2"],"other_free_text":[]},"mechanistic_narrative":"RGS5 is a GTPase-activating protein (GAP) for Gαi and Gαq subunits that functions as a critical modulator of G-protein-coupled receptor signaling in vascular smooth muscle cells, pericytes, and other cell types to regulate vascular tone, remodeling, and tissue homeostasis. RGS5 accelerates GTP hydrolysis on Gαi1/2/3, Gαo, and Gαq, thereby attenuating signaling downstream of angiotensin II/AT1R, endothelin-1, sphingosine-1-phosphate, PDGF, and calcium-sensing receptors, and it suppresses hedgehog signaling by inhibiting Gαi downstream of Smoothened [PMID:11253162, PMID:12006602, PMID:12514120, PMID:23637832, PMID:30690792]. Its stability is controlled by the N-end rule pathway, in which N-terminal Cys-2 oxidation triggers ATE1-mediated arginylation and UBR1/UBR2-dependent proteasomal degradation — a process modulated by hypoxia — while PKC phosphorylation at Ser166 inactivates GAP function, and its N-terminal amphipathic helix is required for membrane targeting [PMID:16217033, PMID:17220356, PMID:17540411, PMID:11253162]. In vivo, Rgs5 loss causes hypotension, prolonged cardiac repolarization, abnormal tumor vasculature, age-dependent myocardial fibrosis through pericyte-derived TGFβ2 secretion, and in astrocytes RGS5 binds TNFR1/TNFR2 to amplify TNF-driven neuroinflammation; in the tumor microenvironment, TGFβ-induced pSmad2 binds RGS5 and sequesters it to the nucleus, switching pericytes from pro-apoptotic to pro-survival signaling [PMID:18268011, PMID:18418378, PMID:23079193, PMID:38563133, PMID:37674228, PMID:34012071]."},"prefetch_data":{"uniprot":{"accession":"O15539","full_name":"Regulator of G-protein signaling 5","aliases":[],"length_aa":181,"mass_kda":20.9,"function":"Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. Binds to G(i)-alpha and G(o)-alpha, but not to G(s)-alpha (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O15539/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RGS5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RGS5","total_profiled":1310},"omim":[{"mim_id":"611392","title":"2-@AMINOETHANETHIOL DIOXYGENASE; ADO","url":"https://www.omim.org/entry/611392"},{"mim_id":"607103","title":"ARGINYLTRANSFERASE 1; ATE1","url":"https://www.omim.org/entry/607103"},{"mim_id":"603276","title":"REGULATOR OF G PROTEIN SIGNALING 5; RGS5","url":"https://www.omim.org/entry/603276"},{"mim_id":"182330","title":"ATPase, Na+/K+ TRANSPORTING, BETA-1 POLYPEPTIDE; ATP1B1","url":"https://www.omim.org/entry/182330"},{"mim_id":"145500","title":"HYPERTENSION, ESSENTIAL","url":"https://www.omim.org/entry/145500"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":1362.9}],"url":"https://www.proteinatlas.org/search/RGS5"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O15539","domains":[{"cath_id":"1.10.167.10","chopping":"56-181","consensus_level":"medium","plddt":97.5971,"start":56,"end":181}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15539","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15539-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15539-F1-predicted_aligned_error_v6.png","plddt_mean":85.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RGS5","jax_strain_url":"https://www.jax.org/strain/search?query=RGS5"},"sequence":{"accession":"O15539","fasta_url":"https://rest.uniprot.org/uniprotkb/O15539.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15539/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15539"}},"corpus_meta":[{"pmid":"18418378","id":"PMC_18418378","title":"Vascular normalization in Rgs5-deficient tumours promotes immune destruction.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/18418378","citation_count":452,"is_preprint":false},{"pmid":"16217033","id":"PMC_16217033","title":"RGS4 and RGS5 are in vivo substrates of the N-end rule pathway.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16217033","citation_count":229,"is_preprint":false},{"pmid":"12598306","id":"PMC_12598306","title":"Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12598306","citation_count":189,"is_preprint":false},{"pmid":"12514120","id":"PMC_12514120","title":"Pericyte-specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation.","date":"2003","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12514120","citation_count":160,"is_preprint":false},{"pmid":"12006602","id":"PMC_12006602","title":"Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12006602","citation_count":99,"is_preprint":false},{"pmid":"10391923","id":"PMC_10391923","title":"The membrane association domain of RGS16 contains unique amphipathic features that are conserved in RGS4 and RGS5.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10391923","citation_count":89,"is_preprint":false},{"pmid":"18268011","id":"PMC_18268011","title":"Rgs5 targeting leads to chronic low blood pressure and a lean body habitus.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18268011","citation_count":77,"is_preprint":false},{"pmid":"17220356","id":"PMC_17220356","title":"N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells.","date":"2007","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17220356","citation_count":75,"is_preprint":false},{"pmid":"11253162","id":"PMC_11253162","title":"Characterization of RGS5 in regulation of G protein-coupled receptor signaling.","date":"2001","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11253162","citation_count":70,"is_preprint":false},{"pmid":"18038251","id":"PMC_18038251","title":"RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.","date":"2007","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18038251","citation_count":70,"is_preprint":false},{"pmid":"18212066","id":"PMC_18212066","title":"Generation and characterization of rgs5 mutant mice.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18212066","citation_count":68,"is_preprint":false},{"pmid":"15095478","id":"PMC_15095478","title":"Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15095478","citation_count":61,"is_preprint":false},{"pmid":"19564336","id":"PMC_19564336","title":"RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19564336","citation_count":61,"is_preprint":false},{"pmid":"22962432","id":"PMC_22962432","title":"PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity.","date":"2012","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22962432","citation_count":54,"is_preprint":false},{"pmid":"17939118","id":"PMC_17939118","title":"Coexpression of Notch3 and Rgs5 in the pericyte-vascular smooth muscle cell axis in response to pulp injury.","date":"2007","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17939118","citation_count":53,"is_preprint":false},{"pmid":"9747037","id":"PMC_9747037","title":"Isolation, tissue expression, and chromosomal assignment of human RGS5, a novel G-protein signaling regulator gene.","date":"1998","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9747037","citation_count":49,"is_preprint":false},{"pmid":"36982915","id":"PMC_36982915","title":"Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36982915","citation_count":48,"is_preprint":false},{"pmid":"22130514","id":"PMC_22130514","title":"Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.","date":"2011","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/22130514","citation_count":42,"is_preprint":false},{"pmid":"17545542","id":"PMC_17545542","title":"Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17545542","citation_count":39,"is_preprint":false},{"pmid":"16293795","id":"PMC_16293795","title":"Expression profiling identifies smooth muscle cell diversity within human intima and plaque fibrous cap: loss of RGS5 distinguishes the cap.","date":"2005","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16293795","citation_count":39,"is_preprint":false},{"pmid":"18207159","id":"PMC_18207159","title":"RGS5, RGS4, and RGS2 expression and aortic contractibility are dynamically co-regulated during aortic banding-induced hypertrophy.","date":"2007","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/18207159","citation_count":34,"is_preprint":false},{"pmid":"34012071","id":"PMC_34012071","title":"RGS5-TGFβ-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34012071","citation_count":31,"is_preprint":false},{"pmid":"24972930","id":"PMC_24972930","title":"RGS5 promotes arterial growth during arteriogenesis.","date":"2014","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24972930","citation_count":31,"is_preprint":false},{"pmid":"39306871","id":"PMC_39306871","title":"RGS5+ lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39306871","citation_count":29,"is_preprint":false},{"pmid":"21881522","id":"PMC_21881522","title":"Association of ATP1B1, RGS5 and SELE polymorphisms with hypertension and blood pressure in African-Americans.","date":"2011","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21881522","citation_count":29,"is_preprint":false},{"pmid":"21965603","id":"PMC_21965603","title":"Origin-specific epigenetic program correlates with vascular bed-specific differences in Rgs5 expression.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/21965603","citation_count":29,"is_preprint":false},{"pmid":"17986358","id":"PMC_17986358","title":"Vascular microarray profiling in two models of hypertension identifies caveolin-1, Rgs2 and Rgs5 as antihypertensive targets.","date":"2007","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17986358","citation_count":29,"is_preprint":false},{"pmid":"21780128","id":"PMC_21780128","title":"The relationship between RGS5 expression and cancer differentiation and metastasis in non-small cell lung cancer.","date":"2011","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21780128","citation_count":29,"is_preprint":false},{"pmid":"21278382","id":"PMC_21278382","title":"Beta-agonist-associated reduction in RGS5 expression promotes airway smooth muscle hyper-responsiveness.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21278382","citation_count":27,"is_preprint":false},{"pmid":"18262772","id":"PMC_18262772","title":"Association of RGS2 and RGS5 variants with schizophrenia symptom severity.","date":"2008","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/18262772","citation_count":27,"is_preprint":false},{"pmid":"23079193","id":"PMC_23079193","title":"Absence of Rgs5 prolongs cardiac repolarization and predisposes to ventricular tachyarrhythmia in mice.","date":"2012","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23079193","citation_count":26,"is_preprint":false},{"pmid":"21105200","id":"PMC_21105200","title":"Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma.","date":"2010","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21105200","citation_count":26,"is_preprint":false},{"pmid":"15670159","id":"PMC_15670159","title":"Identification of a novel alternative splicing variant of RGS5 mRNA in human ocular tissues.","date":"2005","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/15670159","citation_count":25,"is_preprint":false},{"pmid":"38563133","id":"PMC_38563133","title":"Age-Dependent RGS5 Loss in Pericytes Induces Cardiac Dysfunction and Fibrosis.","date":"2024","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/38563133","citation_count":24,"is_preprint":false},{"pmid":"29208700","id":"PMC_29208700","title":"Hypertension-evoked RhoA activity in vascular smooth muscle cells requires RGS5.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29208700","citation_count":24,"is_preprint":false},{"pmid":"29061726","id":"PMC_29061726","title":"Angiotensin II Type 1 Receptor Mechanoactivation Involves RGS5 (Regulator of G Protein Signaling 5) in Skeletal Muscle Arteries: Impaired Trafficking of RGS5 in Hypertension.","date":"2017","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/29061726","citation_count":23,"is_preprint":false},{"pmid":"26558691","id":"PMC_26558691","title":"The pericyte antigen RGS5 in perivascular soft tissue tumors.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26558691","citation_count":20,"is_preprint":false},{"pmid":"21389866","id":"PMC_21389866","title":"Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.","date":"2011","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/21389866","citation_count":20,"is_preprint":false},{"pmid":"34158395","id":"PMC_34158395","title":"ATE1 Inhibits Liver Cancer Progression through RGS5-Mediated Suppression of Wnt/β-Catenin Signaling.","date":"2021","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/34158395","citation_count":19,"is_preprint":false},{"pmid":"30365142","id":"PMC_30365142","title":"RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30365142","citation_count":19,"is_preprint":false},{"pmid":"31605122","id":"PMC_31605122","title":"Down-regulated RGS5 by genetic variants impairs endothelial cell function and contributes to coronary artery disease.","date":"2021","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/31605122","citation_count":17,"is_preprint":false},{"pmid":"15680317","id":"PMC_15680317","title":"Beta adrenergic receptor-mediated atrial specific up-regulation of RGS5.","date":"2004","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15680317","citation_count":17,"is_preprint":false},{"pmid":"27189971","id":"PMC_27189971","title":"Vascular and Central Activation of Peroxisome Proliferator-Activated Receptor-β Attenuates Angiotensin II-Induced Hypertension: Role of RGS-5.","date":"2016","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27189971","citation_count":17,"is_preprint":false},{"pmid":"37674228","id":"PMC_37674228","title":"RGS5 augments astrocyte activation and facilitates neuroinflammation via TNF signaling.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37674228","citation_count":15,"is_preprint":false},{"pmid":"32431860","id":"PMC_32431860","title":"RGS5 plays a significant role in renal cell carcinoma.","date":"2020","source":"Royal Society open science","url":"https://pubmed.ncbi.nlm.nih.gov/32431860","citation_count":15,"is_preprint":false},{"pmid":"37986113","id":"PMC_37986113","title":"RGS5 maintaining vascular homeostasis is altered by the tumor microenvironment.","date":"2023","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/37986113","citation_count":15,"is_preprint":false},{"pmid":"36111549","id":"PMC_36111549","title":"RGS5: a novel role as a hypoxia-responsive protein that suppresses chemokinetic and chemotactic migration in brain pericytes.","date":"2022","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/36111549","citation_count":14,"is_preprint":false},{"pmid":"23144791","id":"PMC_23144791","title":"Atrial tachyarrhythmia in Rgs5-null mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23144791","citation_count":14,"is_preprint":false},{"pmid":"24489801","id":"PMC_24489801","title":"Dlx1 and Rgs5 in the ductus arteriosus: vessel-specific genes identified by transcriptional profiling of laser-capture microdissected endothelial and smooth muscle cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24489801","citation_count":13,"is_preprint":false},{"pmid":"37781234","id":"PMC_37781234","title":"Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection.","date":"2023","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/37781234","citation_count":13,"is_preprint":false},{"pmid":"14504426","id":"PMC_14504426","title":"A culture device demonstrates that hydrostatic pressure increases mRNA of RGS5 in neuroblastoma and CHC1-L in lymphocytic cells.","date":"2003","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/14504426","citation_count":13,"is_preprint":false},{"pmid":"37881333","id":"PMC_37881333","title":"RGS5 as a Biomarker of Pericytes, Involvement in Vascular Remodeling and Pulmonary Arterial Hypertension.","date":"2023","source":"Vascular health and risk management","url":"https://pubmed.ncbi.nlm.nih.gov/37881333","citation_count":12,"is_preprint":false},{"pmid":"17540411","id":"PMC_17540411","title":"Phosphorylation of Ser166 in RGS5 by protein kinase C causes loss of RGS function.","date":"2007","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17540411","citation_count":12,"is_preprint":false},{"pmid":"25810883","id":"PMC_25810883","title":"MicroRNAs that target RGS5.","date":"2015","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25810883","citation_count":10,"is_preprint":false},{"pmid":"28684360","id":"PMC_28684360","title":"Regulator of G protein signaling 5 (RGS5) inhibits sonic hedgehog function in mouse cortical neurons.","date":"2017","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28684360","citation_count":10,"is_preprint":false},{"pmid":"34359918","id":"PMC_34359918","title":"RGS5 Attenuates Baseline Activity of ERK1/2 and Promotes Growth Arrest of Vascular Smooth Muscle Cells.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34359918","citation_count":9,"is_preprint":false},{"pmid":"23637832","id":"PMC_23637832","title":"Regulator of G-protein signaling - 5 (RGS5) is a novel repressor of hedgehog signaling.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23637832","citation_count":9,"is_preprint":false},{"pmid":"27611366","id":"PMC_27611366","title":"Ruminal expression of the NQO1, RGS5, and ACAT1 genes may be indicators of feed efficiency in beef steers.","date":"2016","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27611366","citation_count":9,"is_preprint":false},{"pmid":"30690792","id":"PMC_30690792","title":"Parathyroid-Targeted Overexpression of Regulator of G-Protein Signaling 5 (RGS5) Causes Hyperparathyroidism in Transgenic Mice.","date":"2019","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/30690792","citation_count":8,"is_preprint":false},{"pmid":"37594134","id":"PMC_37594134","title":"Lnc‑RGS5 sponges miR‑542‑5p to promote FoxM1/VEGFA signaling and breast cancer cell proliferation.","date":"2023","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37594134","citation_count":7,"is_preprint":false},{"pmid":"35363396","id":"PMC_35363396","title":"NLGP regulates RGS5-TGFβ axis to promote pericyte-dependent vascular normalization during restricted tumor growth.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35363396","citation_count":7,"is_preprint":false},{"pmid":"35522176","id":"PMC_35522176","title":"miR-320a Targeting RGS5 Aggravates Atherosclerosis by Promoting Migration and Proliferation of ox-LDL-Stimulated Vascular Smooth Muscle Cells.","date":"2022","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35522176","citation_count":6,"is_preprint":false},{"pmid":"26782409","id":"PMC_26782409","title":"Association of regulator of G protein signaling (RGS5) gene variants and essential hypertension in Mongolian and Han populations.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26782409","citation_count":6,"is_preprint":false},{"pmid":"36888549","id":"PMC_36888549","title":"Lineage Tracing of RGS5-CreER-Labeled Cells in Long Bones During Homeostasis and Injury.","date":"2023","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/36888549","citation_count":4,"is_preprint":false},{"pmid":"10733901","id":"PMC_10733901","title":"Molecular cloning and characterization of Xenopus RGS5.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10733901","citation_count":4,"is_preprint":false},{"pmid":"38860604","id":"PMC_38860604","title":"The mechanism of RGS5 regulating gastric cancer mismatch repair protein.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38860604","citation_count":3,"is_preprint":false},{"pmid":"25842189","id":"PMC_25842189","title":"Regulation of RGS5 GAP activity by GPSM3.","date":"2015","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25842189","citation_count":3,"is_preprint":false},{"pmid":"23193110","id":"PMC_23193110","title":"RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients.","date":"2012","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/23193110","citation_count":3,"is_preprint":false},{"pmid":"34502263","id":"PMC_34502263","title":"RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502263","citation_count":3,"is_preprint":false},{"pmid":"33815137","id":"PMC_33815137","title":"Absence of Rgs5 Influences the Spatial and Temporal Fluctuation of Cardiac Repolarization in Mice.","date":"2021","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33815137","citation_count":2,"is_preprint":false},{"pmid":"39746869","id":"PMC_39746869","title":"Germline deletion of Rgs2 and/or Rgs5 in male mice does not exacerbate left ventricular remodeling induced by subchronic isoproterenol infusion.","date":"2025","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/39746869","citation_count":2,"is_preprint":false},{"pmid":"17762159","id":"PMC_17762159","title":"Evidence for the dimerization of human regulator of G-protein signalling 5 (RGS5).","date":"2007","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17762159","citation_count":2,"is_preprint":false},{"pmid":"35946384","id":"PMC_35946384","title":"Hypoxia-induced miR-182-5p regulates vascular smooth muscle cell phenotypic switch by targeting RGS5.","date":"2022","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/35946384","citation_count":1,"is_preprint":false},{"pmid":"39985100","id":"PMC_39985100","title":"A pan-cancer analysis of the oncogenic and immunological roles of RGS5 in clear cell renal cell carcinomas based on in vitro experiment validation.","date":"2025","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/39985100","citation_count":1,"is_preprint":false},{"pmid":"32080025","id":"PMC_32080025","title":"RGS5 rs4657251 polymorphism is associated with small vessel occlusion stroke in Taiwan Han Chinese.","date":"2020","source":"Journal of the Chinese Medical Association : JCMA","url":"https://pubmed.ncbi.nlm.nih.gov/32080025","citation_count":1,"is_preprint":false},{"pmid":"40603753","id":"PMC_40603753","title":"Overexpression of MEOX2 inhibits breast cancer cell metastasis by targeting oxidative stress-induced RGS5.","date":"2025","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/40603753","citation_count":0,"is_preprint":false},{"pmid":"17100651","id":"PMC_17100651","title":"Expression, purification, and preliminary X-ray crystallographic analysis of the complex of G(alphai3)-RGS5 from human with GDP/Mg2+)/AlF4-.","date":"2006","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/17100651","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.20.639333","title":"Integrative Computational Analysis of VCX2 in Hepatocellular Carcinoma: From Potential Biomarker Discovery to Therapeutic Targeting with Peruvian Natural Products","date":"2025-02-26","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.20.639333","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41245,"output_tokens":7660,"usd":0.119318},"stage2":{"model":"claude-opus-4-6","input_tokens":11598,"output_tokens":5018,"usd":0.27516},"total_usd":0.394478,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"RGS5 binds to Gαi1, Gαi2, Gαi3, Gαo, and Gαq (but not Gαs or Gα13) in the presence of GDP/AlF4-, and accelerates the GTPase activity of Gαi3, functioning as a GTPase-activating protein (GAP) for these G-protein subunits.\",\n      \"method\": \"In vitro binding assay with GDP/AlF4-, GTPase activity assay with recombinant proteins\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro GAP activity measurement with defined substrates\",\n      \"pmids\": [\"11253162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RGS5 suppresses angiotensin II- and endothelin-1-induced intracellular Ca2+ transients when expressed in AT1a receptor-expressing 293T cells, confirming its role as a negative regulator of Gq-coupled GPCR signaling.\",\n      \"method\": \"Calcium transient assay in transfected 293T cells overexpressing RGS5\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional assay in defined cellular system with concentration-response relationship\",\n      \"pmids\": [\"11253162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The N-terminal region (amino acids 1–33) of RGS5 is required for membrane targeting; deletion of this region causes RGS5 to localize exclusively to the cytosolic fraction, though GAP activity is retained.\",\n      \"method\": \"Subcellular fractionation of cells expressing full-length vs. ΔN-RGS5\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct fractionation experiment with functional comparison\",\n      \"pmids\": [\"11253162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The N-terminal amphipathic alpha-helix of RGS16 (amino acids 12–30), whose hydrophobic face and positively charged residues are required for membrane association, defines structural features conserved in RGS4 and RGS5, indicating a shared peripheral membrane-targeting mechanism.\",\n      \"method\": \"Site-directed mutagenesis, subcellular fractionation, differential centrifugation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis with fractionation, but RGS5 involvement inferred from conservation rather than directly tested\",\n      \"pmids\": [\"10391923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endogenous RGS5 selectively inhibits angiotensin II AT1a receptor-mediated MAP kinase activation and inositol phosphate release through Gq/11 signaling in rat vascular smooth muscle cells, as demonstrated by ribozyme-mediated knockdown.\",\n      \"method\": \"Synthetic ribozyme knockdown, MAP kinase activation assay, inositol phosphate release assay in rat aortic smooth muscle cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with specific receptor-selective phenotypic readout, replicated across multiple assays\",\n      \"pmids\": [\"12006602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RGS5 acts as a potent GAP for Gαi and Gαq and attenuates angiotensin II-, endothelin-1-, sphingosine-1-phosphate-, and PDGF-induced ERK-2 phosphorylation in pericyte cellular contexts.\",\n      \"method\": \"ERK-2 phosphorylation assay in cells expressing RGS5; correlation with pericyte-specific expression pattern\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional assays across multiple receptor-ligand pairs, consistent with in vitro GAP activity\",\n      \"pmids\": [\"12514120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RGS4 and RGS5 are in vivo substrates of the N-end rule ubiquitin-proteasome pathway: the ATE1 arginyltransferase arginylates oxidized N-terminal Cys-2 of RGS5, targeting it for degradation via ubiquitin ligases UBR1 and UBR2; mutant RGS5 with Cys-2 blocked from becoming N-terminal is long-lived.\",\n      \"method\": \"Genetic (ATE1 knockout, UBR1/UBR2 knockout mice), mutant RGS5 stability assay in vivo and in cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple genetic models, mutagenesis of degradation signal, replicated across RGS4/5/16\",\n      \"pmids\": [\"16217033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Hypoxia perturbs the proteolysis of RGS5 via the N-end rule pathway, implicating an O2-ATE1-UBR1/UBR2 circuit as a mechanism coupling oxygen levels to RGS5 stability and G protein signaling.\",\n      \"method\": \"Cell-based protein stability assay under hypoxic conditions with ATE1 and UBR1/UBR2 knockouts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and cellular models with defined molecular pathway\",\n      \"pmids\": [\"16217033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"N-terminal residues of RGS5 (specifically Cys-2 and the N-end rule determinant) control proteasomal degradation; stabilizing mutation C2S enhances RGS5 expression and function in HEK293 cells.\",\n      \"method\": \"Site-directed mutagenesis (C2S), protein expression quantification, functional assay in HEK293 cells\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis directly linking N-terminal residue to proteasomal degradation and function\",\n      \"pmids\": [\"17220356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Protein kinase C phosphorylates RGS5 at Ser166, abolishing its binding to Gα subunits and its GAP activity; substitution of Ser166 with aspartic acid mimics phosphorylation and markedly reduces inhibition of ET-1-induced Ca2+ responses.\",\n      \"method\": \"In vitro PKC phosphorylation assay, mass spectrometry, site-directed mutagenesis (S166D), Ca2+ assay, Gα binding assay\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay, mass spec identification of phosphosite, mutagenesis with functional readout\",\n      \"pmids\": [\"17540411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of Rgs5 in mice results in persistently low blood pressure and dilated aortas; isolated aortic smooth muscle cells from Rgs5-/- mice show exaggerated phosphorylation of VASP and ERK in response to sodium nitroprusside or sphingosine-1-phosphate, indicating RGS5 attenuates vasodilatory signaling.\",\n      \"method\": \"Rgs5 knockout mouse, blood pressure measurement, aortic smooth muscle cell isolation, phosphorylation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with specific molecular phenotypes in isolated cells\",\n      \"pmids\": [\"18268011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of Rgs5 in tumors leads to pericyte maturation and vascular normalization, reducing tumor hypoxia and vessel leakiness, and increasing immune effector cell infiltration, establishing RGS5 as a master regulator of abnormal tumor vascular morphology through G-protein signaling.\",\n      \"method\": \"Rgs5 knockout mouse tumor model, histology, vascular permeability assay, immune cell infiltration analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO with multiple orthogonal phenotypic readouts, highly cited foundational study\",\n      \"pmids\": [\"18418378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RGS5 is a HIF-1-dependent hypoxia-inducible gene in endothelial cells; overexpression of RGS5 induces apoptosis via caspase-3 activation and increased Bax/Bcl-2 ratio, and antagonizes VEGF angiogenic signaling by activating p38 (but not ERK1/2).\",\n      \"method\": \"HIF-1β knockout cells, RGS5 overexpression, siRNA knockdown, Annexin V assay, caspase-3 activation assay, p38 inhibitor, Matrigel assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (OE, KD, KO cell line, in vivo Matrigel) with defined pathway\",\n      \"pmids\": [\"19564336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Beta-agonist exposure of airway smooth muscle cells reduces RGS5 expression, leading to augmented procontractile signaling; RGS5 knockdown increases agonist-evoked intracellular Ca2+ flux and myosin light chain phosphorylation, and Rgs5-/- mouse lung slices contract more to carbachol.\",\n      \"method\": \"siRNA knockdown, Ca2+ flux assay, MLC phosphorylation assay, Rgs5 KO mouse lung slice contraction assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KD and KO with mechanistically defined cellular phenotypes\",\n      \"pmids\": [\"21278382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RGS5 is a transcriptional target of PPARγ and PPARδ in vascular smooth muscle cells; RGS5 blunts angiotensin II-mediated protein kinase C activation and preserves large conductance Ca2+-activated K+ (BKCa) channel activity, thereby controlling myogenic tone in mesenteric arteries.\",\n      \"method\": \"Gene expression profiling, PPAR response element binding assay, siRNA targeting RGS5, patch clamp, myogenic tone measurement in transgenic mice with dominant-negative PPARγ\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking PPARγ→RGS5→PKC→BKCa signaling axis\",\n      \"pmids\": [\"22962432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RGS5 acts as an endogenous repressor of hedgehog signaling: RGS5 overexpression inhibits Shh-mediated signaling and osteogenesis in C3H10T1/2 cells, while siRNA-mediated knockdown potentiates Shh signaling; RGS5 co-immunoprecipitates with Smoothened (Smo) and co-localizes with Smo in primary cilia.\",\n      \"method\": \"Overexpression, siRNA knockdown, co-immunoprecipitation, immunohistochemical analysis of primary cilia, osteogenesis assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP, OE and KD with functional readout, localization in primary cilia\",\n      \"pmids\": [\"23637832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RGS5 promotes arteriogenesis by inhibiting Gαq/11-mediated calcium mobilization in vascular smooth muscle cells, thereby enabling Gα12/13-mediated RhoA signaling required for SMC proliferation and acquisition of an activated phenotype; knockdown of RGS5 blocks RhoA activation and impairs collateral growth.\",\n      \"method\": \"RGS5 overexpression, siRNA knockdown, RhoA activation assay, calcium mobilization assay, Rgs5-deficient mice, collateral arteriole growth measurement\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established through OE/KD/KO with multiple orthogonal assays\",\n      \"pmids\": [\"24972930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPSM3 (AGS4/G18) directly binds RGS5 selectively and enhances RGS5-mediated acceleration of GTP hydrolysis by Gαi1 in solution-based assays, while in membrane-based assays the binding of RGS5 to GPSM3 impedes GPSM3's inhibitory effect on GTP turnover.\",\n      \"method\": \"Co-immunoprecipitation, in vitro GTPase assay, membrane-based GTPase assay with M2 muscarinic receptor\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro biochemical assay with direct binding, single lab\",\n      \"pmids\": [\"25842189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RGS5 localizes to and physically associates with the angiotensin II type 1 receptor (AT1R) in vascular smooth muscle cells upon AT1R activation (by AngII or mechanical stimulation), as demonstrated by proximity ligation assay; siRNA knockdown of RGS5 enhances AngII-induced constriction and myogenic responses; translocation of RGS5 to AT1R is impaired in spontaneously hypertensive rats.\",\n      \"method\": \"In situ proximity ligation assay, siRNA knockdown in intact arterioles, myogenic response measurement, candesartan competition\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct physical interaction assay in primary VSMCs with functional loss-of-function validation\",\n      \"pmids\": [\"29061726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Hypertensive pressure/stretch increases RGS5 expression in vascular smooth muscle cells; RGS5 is required for hypertension-induced RhoA activation and stress fiber formation through its inhibition of Gαq/11 signaling, thereby enabling the synthetic VSMC phenotype; PKC inhibition mimics RGS5-mediated effects on RhoA.\",\n      \"method\": \"Rgs5 KO mice, mechanical stretch experiments, RhoA activation assay, PKC inhibition, SMC phenotype markers\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO model with mechanistic dissection of Gαq/11→PKC→RhoA pathway\",\n      \"pmids\": [\"29208700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In the tumor microenvironment, TGFβ causes pSmad2 to bind RGS5 and traffics it to the nucleus, suppressing both RGS5-Gαi/q signaling and pSmad2/3-Smad4 pairing; this switches RGS5 from pro-apoptotic to anti-apoptotic by rescuing PI3K-AKT signaling and preventing mitochondrial damage/caspase activation in tumor pericytes.\",\n      \"method\": \"Co-immunoprecipitation, nuclear fractionation, PI3K-AKT signaling assay, apoptosis assays (Bcl2, PUMA, Bax, caspase), pericyte survival assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding and functional assays defining a novel RGS5-TGFβ-Smad2 signaling axis\",\n      \"pmids\": [\"34012071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ATE1-mediated arginylation controls RGS5 turnover, which in turn regulates β-catenin stability via GSK3-β; RGS5 loss-of-function or gain-of-function modulates Wnt/β-catenin signaling in liver cancer cells, with CHIR99021 (GSK3-β inhibitor) cooperative effects confirming the pathway order.\",\n      \"method\": \"Loss- and gain-of-function (lentivirus, siRNA), co-immunoprecipitation with β-catenin, GSK3-β inhibitor epistasis\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis and OE/KD with pathway placement, single lab\",\n      \"pmids\": [\"34158395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RGS5 overexpression in proliferating VSMCs attenuates ERK1/2 and Akt phosphorylation and promotes a resting/quiescent phenotype; selective inhibition of Gαi/o (but not Gαq/11) mimics this effect, indicating RGS5 maintains VSMC growth arrest primarily through Gαi/o suppression.\",\n      \"method\": \"RGS5 overexpression, microarray-based expression profiling, Gαi/o and Gαq/11 selective inhibitors, ERK1/2 and Akt phosphorylation assays, proliferation and migration assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of G-protein subtype with OE and multiple functional readouts\",\n      \"pmids\": [\"34359918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RGS5 acts as a hypoxia-responsive protein in human brain pericytes that is stabilized under hypoxia independently of HIF-1α; RGS5 expression desensitizes pericytes to PDGFBB and sphingosine-1-phosphate signaling, blocking chemokinesis and chemotaxis induced by these factors.\",\n      \"method\": \"Hypoxia experiments with HIF-1α inhibition, PDGFBB/S1P chemokinesis and chemotaxis assays, RGS5 overexpression in brain pericytes\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays in primary cells with HIF-1α independence shown, single lab\",\n      \"pmids\": [\"36111549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RGS5 inhibits calcium-sensing receptor (CASR) signaling in parathyroid cells; overexpression of RGS5 in parathyroid gland causes hyperparathyroidism, parathyroid neoplasia, and elevated PTH in transgenic mice, while RGS5-null mice have abnormally low PTH levels.\",\n      \"method\": \"Transgenic mouse overexpressing RGS5 in parathyroid, Rgs5-null mouse, CASR signaling assay in normal human parathyroid cells\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — both overexpression and KO mouse models with defined CASR signaling mechanism\",\n      \"pmids\": [\"30690792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RGS5 inhibits Sonic Hedgehog (Shh) signaling in cortical neurons: RGS5 overexpression reduces neurite outgrowth and FM4-64 uptake (presynaptic terminal function) and affects cAMP-PKA signaling, consistent with its GAP activity on Gαi downstream of Smo.\",\n      \"method\": \"Adenoviral RGS5 overexpression in primary cortical neurons, neurite outgrowth quantification, FM4-64 uptake assay, cAMP-PKA assay\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional neuronal assays with OE, single lab\",\n      \"pmids\": [\"28684360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RGS5 promotes neuroinflammation by binding directly to TNFR1 and TNFR2 in astrocytes, augmenting TNF signaling-mediated pro-inflammatory cytokine production; selective ablation of Rgs5 in astrocytes mitigates neuroinflammatory response in Parkinson's disease models.\",\n      \"method\": \"Astrocyte-specific Rgs5 conditional knockout, Rgs5 overexpression, Co-immunoprecipitation of RGS5 with TNFR1/TNFR2, cytokine production assays, PD animal models\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-specific KO + OE + direct physical interaction (Co-IP) with defined functional readouts\",\n      \"pmids\": [\"37674228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Age-dependent loss of RGS5 in cardiac pericytes impairs cardiac function and induces myocardial fibrosis; RGS5-deficient pericytes adopt a profibrotic gene expression signature, secreting TGFB2 and PDGFB, and the conditioned medium activates fibroblasts (αSMA induction) in a TGFβ2-dependent manner.\",\n      \"method\": \"In vivo RGS5 deletion, pericyte-fibroblast co-culture, supernatant transfer experiment, TGFβ2 neutralization, single-nucleus RNA sequencing, histological analysis\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO + in vitro co-culture + mechanistic rescue experiments\",\n      \"pmids\": [\"38563133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The complex of human Gαi3 and RGS5 with GDP/Mg2+/AlF4- was crystallized at 3.0 Å resolution (space group P4(1)2(1)2, unit cell a=b=95.9 Å, c=138.8 Å), providing preliminary structural characterization of the RGS5-Gαi3 interaction.\",\n      \"method\": \"Protein overexpression in E. coli, complex crystallization, X-ray crystallography (synchrotron source)\",\n      \"journal\": \"Protein and peptide letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 1 method but only preliminary crystallographic report without functional validation\",\n      \"pmids\": [\"17100651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A novel splice variant of RGS5 (RGS5s), lacking 108 N-terminal amino acids, localizes exclusively to the cytosolic fraction unlike full-length RGS5, and fails to inhibit Gαq-coupled AT1 or FP receptor Ca2+ signaling; co-transfection of RGS5s with RGS5 competitively blocks full-length RGS5 function.\",\n      \"method\": \"RT-PCR cloning, subcellular fractionation, Ca2+ signaling assay, co-transfection competition assay in HEK293 cells\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct fractionation and functional assay with dominant-negative characterization\",\n      \"pmids\": [\"15670159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RGS5 forms a homodimer in addition to its monomeric form; the dimer is longer-lived than the monomer, suggesting it may serve a regulatory function in GPCR signaling.\",\n      \"method\": \"Western blot, GFP-tagged RGS5 yeast assay, two-hybrid assay, HEK293A cell analysis\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — dimerization shown by multiple methods but functional significance only inferred from stability\",\n      \"pmids\": [\"17762159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of Rgs5 in mice results in prolonged cardiac repolarization (extended QT interval and action potential duration), reduced outward voltage-dependent K+ currents (Ito, IKur, Iss), and downregulated Kv4.2, Kv4.3, Kv1.5, and Kv2.1, predisposing to ventricular tachyarrhythmia.\",\n      \"method\": \"Rgs5 KO mouse, in vivo/in vitro electrophysiology, whole-cell patch clamp, Western blot and transcript analysis of Kv channels\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with direct electrophysiological measurements at organ, cell, and molecular levels\",\n      \"pmids\": [\"23079193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RGS5 co-immunoprecipitates with c-Myc in gastric cancer cells and regulates c-Myc protein levels through the ubiquitin-proteasome pathway, thereby controlling mismatch repair protein expression and PD-L1 levels.\",\n      \"method\": \"Co-immunoprecipitation of RGS5 and c-Myc, ubiquitin-proteasome pathway inhibition, Western blot\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with limited mechanistic follow-up\",\n      \"pmids\": [\"38860604\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RGS5 is a peripheral membrane-associated GTPase-activating protein (GAP) for Gαi and Gαq subunits, whose N-terminal region (including a conserved amphipathic helix) directs membrane targeting; its stability is regulated by the N-end rule pathway through sequential N-terminal Cys-2 oxidation, arginylation by ATE1, and proteasomal degradation via UBR1/UBR2, while PKC phosphorylation at Ser166 inactivates its GAP function; in vascular smooth muscle cells and pericytes, RGS5 selectively attenuates angiotensin II/AT1R, endothelin-1, sphingosine-1-phosphate, and PDGF-mediated signaling to regulate arterial tone, vascular remodeling (via Gαq/11→PKC suppression enabling Gα12/13→RhoA activation), and blood pressure, and also suppresses hedgehog signaling via Gαi inhibition downstream of Smoothened, binds TNFR1/TNFR2 in astrocytes to amplify TNF-driven neuroinflammation, and in the tumor microenvironment is co-opted by TGFβ through pSmad2-RGS5 nuclear complex formation to switch from pro-apoptotic to pro-survival signaling in pericytes.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"RGS5 is a GTPase-activating protein (GAP) for Gαi and Gαq subunits that functions as a critical modulator of G-protein-coupled receptor signaling in vascular smooth muscle cells, pericytes, and other cell types to regulate vascular tone, remodeling, and tissue homeostasis. RGS5 accelerates GTP hydrolysis on Gαi1/2/3, Gαo, and Gαq, thereby attenuating signaling downstream of angiotensin II/AT1R, endothelin-1, sphingosine-1-phosphate, PDGF, and calcium-sensing receptors, and it suppresses hedgehog signaling by inhibiting Gαi downstream of Smoothened [PMID:11253162, PMID:12006602, PMID:12514120, PMID:23637832, PMID:30690792]. Its stability is controlled by the N-end rule pathway, in which N-terminal Cys-2 oxidation triggers ATE1-mediated arginylation and UBR1/UBR2-dependent proteasomal degradation — a process modulated by hypoxia — while PKC phosphorylation at Ser166 inactivates GAP function, and its N-terminal amphipathic helix is required for membrane targeting [PMID:16217033, PMID:17220356, PMID:17540411, PMID:11253162]. In vivo, Rgs5 loss causes hypotension, prolonged cardiac repolarization, abnormal tumor vasculature, age-dependent myocardial fibrosis through pericyte-derived TGFβ2 secretion, and in astrocytes RGS5 binds TNFR1/TNFR2 to amplify TNF-driven neuroinflammation; in the tumor microenvironment, TGFβ-induced pSmad2 binds RGS5 and sequesters it to the nucleus, switching pericytes from pro-apoptotic to pro-survival signaling [PMID:18268011, PMID:18418378, PMID:23079193, PMID:38563133, PMID:37674228, PMID:34012071].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing the structural basis for membrane targeting: mutagenesis of RGS16 defined an N-terminal amphipathic helix whose hydrophobic face and charged residues are required for peripheral membrane association, a feature conserved in RGS5.\",\n      \"evidence\": \"Site-directed mutagenesis and subcellular fractionation of RGS16, with conservation analysis to RGS4/RGS5\",\n      \"pmids\": [\"10391923\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The amphipathic helix was characterized in RGS16, not RGS5 directly\", \"Lipid-binding specificity of the helix is unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defining RGS5 as a selective GAP for Gαi and Gαq established its core biochemical activity and showed it suppresses Gq-coupled GPCR (AT1R, ET-1) calcium signaling, answering which G-protein subtypes it acts on.\",\n      \"evidence\": \"In vitro GAP assay with recombinant proteins; calcium transient assays in AT1a-expressing 293T cells; subcellular fractionation showing N-terminal 33 residues required for membrane targeting\",\n      \"pmids\": [\"11253162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural detail of Gα–RGS5 interface at this point\", \"Endogenous relevance in native cells not yet shown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Loss-of-function in native vascular smooth muscle cells demonstrated that endogenous RGS5 selectively restrains AT1R-Gq/11 signaling (MAPK, inositol phosphate) but not other GPCRs, establishing receptor selectivity in a physiological context.\",\n      \"evidence\": \"Ribozyme-mediated RGS5 knockdown in rat aortic smooth muscle cells with MAPK and IP release readouts\",\n      \"pmids\": [\"12006602\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of receptor selectivity (direct AT1R interaction vs. subcellular compartmentalization) unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Broadening the ligand repertoire showed RGS5 attenuates signaling from multiple GPCR agonists (AngII, ET-1, S1P, PDGF) relevant to pericyte biology, positioning it as a multi-receptor signaling brake in the vasculature.\",\n      \"evidence\": \"ERK-2 phosphorylation assays across multiple ligands in pericyte-relevant cellular contexts\",\n      \"pmids\": [\"12514120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pericyte-specific phenotypic consequences not yet tested in vivo\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The discovery that RGS5 is degraded via the N-end rule pathway — requiring Cys-2 oxidation, ATE1-mediated arginylation, and UBR1/UBR2 ubiquitin ligases — and that hypoxia perturbs this degradation, revealed an oxygen-sensing mechanism controlling RGS5 protein levels.\",\n      \"evidence\": \"ATE1-KO and UBR1/UBR2-KO mice, Cys-2 mutant stability assays, hypoxia experiments\",\n      \"pmids\": [\"16217033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the oxidase acting on Cys-2 remains unknown\", \"In vivo vascular consequences of hypoxia-stabilized RGS5 not directly tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"A short splice variant (RGS5s) lacking 108 N-terminal residues is cytosolic and GAP-inactive, and acts as a dominant-negative competitor, revealing a potential endogenous regulatory mechanism.\",\n      \"evidence\": \"RT-PCR cloning, fractionation, calcium assays, and co-transfection competition in HEK293 cells\",\n      \"pmids\": [\"15670159\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological expression levels and tissue distribution of RGS5s unclear\", \"In vivo relevance of dominant-negative function not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of PKC-mediated phosphorylation at Ser166 as a switch that abolishes Gα binding and GAP activity provided a feedback mechanism by which Gαq→PKC signaling can inactivate its own negative regulator.\",\n      \"evidence\": \"In vitro PKC assay, mass spectrometry of Ser166, S166D phosphomimetic mutagenesis with Ca2+ and Gα-binding readouts\",\n      \"pmids\": [\"17540411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which PKC isoform(s) are responsible in vivo is not defined\", \"Whether Ser166 phosphorylation is reversible by specific phosphatases is unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Rgs5-knockout mice revealed two major in vivo roles: systemic hypotension with exaggerated vasodilatory signaling in aortic SMCs, and pericyte-driven tumor vascular normalization upon RGS5 loss, establishing RGS5 as a regulator of both arterial tone and tumor vasculature.\",\n      \"evidence\": \"Rgs5-KO mice with blood pressure measurement, aortic SMC phosphorylation assays; tumor transplant models with vascular permeability, immune infiltration, and histology\",\n      \"pmids\": [\"18268011\", \"18418378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors mediating tumor vascular normalization not fully delineated\", \"Whether RGS5 loss affects immune evasion independently of vascular normalization is unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"RGS5 was identified as a HIF-1-dependent hypoxia-responsive gene that induces caspase-3-mediated apoptosis and antagonizes VEGF signaling via p38 activation, linking its expression to oxygen-sensing transcriptional programs.\",\n      \"evidence\": \"HIF-1β-KO endothelial cells, RGS5 overexpression and siRNA knockdown, Annexin V and caspase-3 assays, p38 inhibitor studies\",\n      \"pmids\": [\"19564336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HIF-1-dependent transcription and N-end rule protein stabilization operate synergistically or redundantly under hypoxia\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Two new physiological roles were defined: RGS5 controls cardiac repolarization via regulation of voltage-dependent K+ channels (Kv4.2/4.3, Kv1.5, Kv2.1), and in VSMCs it is a PPARγ/δ transcriptional target that preserves BKCa channel activity to control myogenic tone by suppressing PKC.\",\n      \"evidence\": \"Rgs5-KO mouse electrophysiology (QT prolongation, patch clamp, Kv channel expression); PPARγ response element binding, siRNA, patch clamp, myogenic tone in transgenic mice\",\n      \"pmids\": [\"23079193\", \"22962432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking RGS5 loss to Kv channel downregulation is indirect — whether transcriptional or post-translational is unknown\", \"Whether PPARγ regulation of RGS5 is relevant outside the mesenteric vasculature\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"RGS5 was shown to repress hedgehog signaling by co-immunoprecipitating with Smoothened and co-localizing in primary cilia, with overexpression inhibiting and knockdown potentiating Shh-mediated osteogenesis, extending its function beyond classical Gαi/q signaling.\",\n      \"evidence\": \"Co-IP, immunohistochemistry in primary cilia, OE and siRNA in C3H10T1/2 cells with osteogenesis readout\",\n      \"pmids\": [\"23637832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RGS5 acts on Gαi downstream of Smo or through a direct Smo interaction is unresolved\", \"In vivo hedgehog-related phenotype in Rgs5-KO mice not reported\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A signaling switch model was established: RGS5 preferentially inhibits Gαq/11→PKC, thereby enabling Gα12/13→RhoA signaling in VSMCs — explaining how RGS5 promotes arteriogenesis by balancing competing G-protein pathways rather than uniformly suppressing all signaling.\",\n      \"evidence\": \"OE/KD/KO approaches with RhoA activation, calcium mobilization, and collateral arteriole growth measurements\",\n      \"pmids\": [\"24972930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RGS5 achieves selectivity for Gαq/11 over Gα12/13 at the structural level is unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Proximity ligation demonstrated that RGS5 physically associates with AT1R upon activation in VSMCs, and this translocation is impaired in spontaneously hypertensive rats, providing a mechanism for receptor-proximal GAP activity and its failure in hypertension.\",\n      \"evidence\": \"In situ PLA in primary VSMCs, siRNA knockdown with myogenic response measurement, comparison of normotensive vs. SHR arterioles\",\n      \"pmids\": [\"29061726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether impaired RGS5 translocation in SHR is cause or consequence of hypertension\", \"Direct binding interface between RGS5 and AT1R not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mechanical stretch/hypertensive pressure was shown to upregulate RGS5 in VSMCs, which then enables RhoA-mediated stress fiber formation through Gαq/11 suppression, establishing RGS5 as a mechanosensitive effector of vascular remodeling.\",\n      \"evidence\": \"Rgs5-KO mice under hypertension, mechanical stretch of VSMCs, RhoA assay, PKC inhibitor phenocopy\",\n      \"pmids\": [\"29208700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional mechanism by which stretch induces RGS5 expression is not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"RGS5 inhibits calcium-sensing receptor signaling in parathyroid cells: transgenic overexpression causes hyperparathyroidism and parathyroid neoplasia while Rgs5-null mice have low PTH, revealing an endocrine role beyond the vasculature.\",\n      \"evidence\": \"Parathyroid-targeted RGS5 transgenic and Rgs5-null mice, CASR signaling in human parathyroid cells\",\n      \"pmids\": [\"30690792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RGS5 acts on Gαi or Gαq downstream of CASR is not dissected\", \"Relevance to human parathyroid disease not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"TGFβ-induced pSmad2 was found to bind RGS5 and sequester it to the nucleus in tumor pericytes, switching RGS5 from a pro-apoptotic to pro-survival factor by rescuing PI3K-AKT signaling, revealing how the tumor microenvironment co-opts RGS5.\",\n      \"evidence\": \"Co-IP of pSmad2–RGS5, nuclear fractionation, PI3K-AKT and apoptosis assays in tumor pericytes\",\n      \"pmids\": [\"34012071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether nuclear RGS5 has transcriptional or other nuclear functions beyond Smad2 sequestration\", \"Generalizability across tumor types not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"RGS5 overexpression in proliferating VSMCs was shown to promote quiescence primarily through Gαi/o suppression (attenuating ERK1/2 and Akt), pharmacologically dissecting which Gα subtype mediates the growth-arrest phenotype.\",\n      \"evidence\": \"OE with selective Gαi/o vs. Gαq/11 inhibitors, ERK/Akt phosphorylation, proliferation and migration assays\",\n      \"pmids\": [\"34359918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the Gαi-coupled receptor driving VSMC proliferation that RGS5 opposes is not specified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A non-canonical, G-protein-independent function was identified: RGS5 directly binds TNFR1 and TNFR2 in astrocytes to amplify TNF-driven neuroinflammation, and astrocyte-specific Rgs5 deletion mitigates neuroinflammation in Parkinson's disease models.\",\n      \"evidence\": \"Astrocyte-specific conditional Rgs5-KO, Co-IP of RGS5 with TNFR1/TNFR2, cytokine assays, PD animal models\",\n      \"pmids\": [\"37674228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which RGS5 binding to TNFRs amplifies signaling (scaffolding, receptor stabilization?) is undefined\", \"Whether this is Gα-dependent or entirely independent is unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Age-dependent loss of RGS5 in cardiac pericytes was shown to drive myocardial fibrosis through secretion of TGFβ2 and PDGFB, which activate fibroblasts in a paracrine manner, establishing RGS5 as a guardian against cardiac aging.\",\n      \"evidence\": \"In vivo Rgs5 deletion, pericyte-fibroblast co-culture, TGFβ2 neutralization rescue, snRNA-seq, histology\",\n      \"pmids\": [\"38563133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What triggers age-dependent RGS5 downregulation in pericytes is unknown\", \"Whether restoring RGS5 can reverse established fibrosis is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of RGS5 selectivity for Gαq/11 over Gα12/13, the identity of the Cys-2 oxidase, whether nuclear RGS5–pSmad2 complexes have transcriptional roles, and the mechanism by which RGS5 binding to TNFRs amplifies rather than dampens signaling.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of full-length RGS5 or its TNFR complexes\", \"Cys-2 oxidase identity unknown\", \"Nuclear function of RGS5 beyond Smad sequestration uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 4, 5, 9, 16, 22]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 29]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4, 5, 9, 15, 16, 18, 22, 24, 25]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6, 7, 8]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [12, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [26]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [15, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNAI3\",\n      \"GNAQ\",\n      \"ATE1\",\n      \"UBR1\",\n      \"UBR2\",\n      \"SMO\",\n      \"TNFRSF1A\",\n      \"SMAD2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}